Jazz Pharmaceuticals plc (Nasdaq:JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. In these areas, Jazz Pharmaceuticals markets Xyrem®(sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio®(defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase®, Defitelio® (defibrotide) and Vyxeos®44 mg/100 mg powder for concentrate for solution for infusion in countries outside the U.S.
